Continue reading Closing Bell: A Hard Day on Hard Data (GERN, PAR, DELL, HPQ, BAC, MDT, MTH, RIMM)

Closing Bell: A Hard Day on Hard Data (GERN, PAR, DELL, HPQ, BAC, MDT, MTH, RIMM) originally appeared on BloggingStocks on Tue, 24 Aug 2010 16:20:00 EST. Please see our terms for use of feeds.

"Geron (GERN) is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes," says Tom Bishop.

In his BI Research advisory he explains, "The company is also a, if not the, world leader in the development of human embryonic stem cell-based therapeutics." Here's his in-deth analysis of the company.

Continue reading Geron (GERN): 'First in Class' in Stem Cell Research

Geron (GERN): 'First in Class' in Stem Cell Research originally appeared on BloggingStocks on Fri, 15 Jan 2010 13:00:00 EST. Please see our terms for use of feeds.

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

"NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

Continue reading Nuvasive (NUVA): Growth in adult stem cells

Nuvasive (NUVA): Growth in adult stem cells originally appeared on BloggingStocks on Fri, 03 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

Just as President Obama lifted the executive order banning the use of embryonic stem cells for research, Roche and Genentech (NYSE: DNA) appear to have reached an agreement on Roche's bid to acquire the 44% of DNA that Roche does not currently own.

Shares of biotech companies engaged in stem cell protocols rallied after the Obama announcement. While most of these companies are small in size with stock prices below $2 per share, the announcement gave impetus to price increases of 17% to 100%.

Continue reading Beware biotech

Beware biotech originally appeared on BloggingStocks on Tue, 10 Mar 2009 14:40:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: Merger Mania fails to wake buyers (BAC, C, GE, DNA, GERN, HGSI, WFC)

Closing Bell: Merger Mania fails to wake buyers (BAC, C, GE, DNA, GERN, HGSI, WFC) originally appeared on BloggingStocks on Mon, 09 Mar 2009 16:00:00 EST. Please see our terms for use of feeds.

Do not underestimate the power of a new administration in Washington. With the ability to spend a huge amount of dollars, team Obama can wield tremendous influence in the market.

Case in point is the stem cell space. It is widely expected that Obama will issue an executive order eliminating restrictions on stem cell research.

Stocks like StemCells Inc. (NASDAQ: STEM) and Geron Corp. (NASDAQ: GERN) have been moving higher since the inaugural.

Coincidentally, on Friday, GERN announced approval for human trials for its treatment of spinal chord injuries using stem cells. Both GERN and STEM were up big as a result.

Another space expected to do well under the Obama administration is construction. A massive stimulus plan is said to be coming in February. A key point of the plan will be to boost infrastructure spending.

The dollars will benefit companies like Fluor Corp. (NYSE: FLR) and Jacobs Engineering (NYSE: JEC). Unlike stem cells, the market has yet to move these stocks higher. FLR is down more than 10% and JEC is down nearly 18% so far this year.

Continue reading Missed the stem cell move? Make a play at Jacobs Engineering

Missed the stem cell move? Make a play at Jacobs Engineering originally appeared on BloggingStocks on Sat, 24 Jan 2009 12:40:00 EST. Please see our terms for use of feeds.

Obama pick follow-up: StemCell bouncing higher originally appeared on BloggingStocks on Fri, 23 Jan 2009 14:15:00 EST. Please see our terms for use of feeds.

Continue reading Obama Pick: StemCells Inc.

Obama Pick: StemCells Inc. originally appeared on BloggingStocks on Wed, 05 Nov 2008 15:15:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Last November, Google Inc (NASDAQ: GOOG) and 30 partners were said be developing a new type of handset using Android that was expected to revolutionize the industry. The first new phones were expected to be available in this year's second half but are now slated for the fourth quarter the Wall Street Journal reported.
• According to people familiar with the situation, the Wall Street Journal reported that Citigroup Incorporated (NYSE: C) will make sharp cuts in its investment banking division this week.
• The Wall Street Journal reported that Live Nation Inc's (NYSE: LYV) Chairman, Michael Cohl, stepped down down as a director and executive to end the strategy feud with CEO Michael Rapino. over how to pursue the "360 deals" with music superstars.
• The Financial Times reported that there are worries that investment banks will accelerate the pace of their layoffs this summer, after it became known that The Goldman Sachs Group Inc (NYSE: GS) gave pink slips to workers in its investment banking division last week. Goldman is now expected to lay off up to 10% of the workers at the division.

• New Jersey put its $150M center for stem cell research on hold, the Star Ledger reported, eight months after ground was broken on the project.

Newspaper wrap-up: Google's plans for cellphone delayed originally appeared on BloggingStocks on Mon, 23 Jun 2008 08:47:00 EST. Please see our terms for use of feeds.

Silence of the (partially human??) lambs originally appeared on BloggingStocks on Tue, 27 Mar 2007 12:06:00 EST. Please see our terms for use of feeds.